Insmed Announces Upcoming Data Presentations at Infectious Disease Week 2015
06 Octobre 2015 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the needs of patients with rare diseases, today
reported new nontuberculous mycobacteria (NTM) lung disease
information will be presented at the Infectious Disease Week 2015
(IDWeek) meeting taking place in San Diego, California from October
7-11. IDWeek is the combined annual meeting of the Infectious
Diseases Society of America, Society for Healthcare Epidemiology of
America, HIV Medicine Association, and Pediatric Infectious
Diseases Society.
Summarized below is the poster title and presentation time. Full
abstracts for the meeting can be found on the IDWeek website at
http://www.idweek.org/.
Presentation Title: Nontuberculous Mycobacteria
Lung Infections: Pre-index Comorbidity and Utilization Patterns at
a Large US Health PlanLead Author: W. Holte, MD
Poster Number: 574Date: Thursday,
October 8, 2015Session Time: 12:30-2:00 PM
PTSession Title: TB: Nontuberculous Mycobacterial
Infections
The posters will be made available on the
company’s website after presentation at the meeting.
About Insmed
Insmed Incorporated is a global
biopharmaceutical company focused on the needs of patients with
rare diseases. The company is advancing a global phase 3 clinical
study of ARIKAYCE™ (liposomal amikacin for inhalation) in
nontuberculous mycobacteria (NTM) lung disease, a rare and often
chronic infection that can lead to progressive inflammation and
lung damage. There are no currently approved treatments for NTM in
the United States or European Union (EU). In the EU, the
company has filed a marketing authorization application seeking
approval of ARIKAYCE for use in patients with NTM, as well as in
cystic fibrosis patients with Pseudomonas aeruginosa lung
infections. Insmed’s earlier-stage pipeline includes INS1009, a
nebulized prodrug formulation of treprostinil that the company is
developing for the treatment of pulmonary arterial hypertension
(PAH), a chronic, life-threatening disorder characterized by
abnormally high blood pressure in the arteries between the heart
and lungs. To complement its internal research, Insmed actively
seeks in-licensing opportunities for a broad range of rare
diseases. For more information visit www.insmed.com.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024